CT引导下经皮穿刺植入放射性^(125)I粒子治疗肺癌的临床评价  

The clinic value of CT-guided interstitial ^(125)I seeds implantation for lung cancer

作　　者：崔亚利[1] 杨光 王颖[1] 

机构地区：[1]哈尔滨医科大学第三临床医学院核医学科,黑龙江哈尔滨150081 [2]黑龙江省林业总医院检验科,黑龙江哈尔滨150080

出　　处：《哈尔滨医科大学学报》2008年第4期400-402,共3页Journal of Harbin Medical University

基　　金：黑龙江省教育厅科研课题(11511182)

摘　　要：目的探讨CT引导下经皮穿刺植入放射性125I粒子的治疗方法并评价其临床疗效。方法经CT引导125I粒子植入治疗肺癌102例。所有病例术前根据肿瘤的大小利用TPS制定治疗计划,计算出所需125I粒子的最佳数量术后质量验证。1月复查CT及临床观察毒副反应。结果植入病例全部成功,1月复查CT及临床观察无毒副反应,CR 76.3%、PR 17.7%、SD 4.1%、PD 1.9%。中位生存期大于12个月。结论CT引导下经皮穿刺放射性125I粒子组织间照射治疗肺癌安全、疗效可靠,并且创伤小、并发症少。Objective To introduce the procedures and evaluate the clinic value of CT-guided interstitial ^125I seeds implantation in treatment of lung cancer. Methods One hundred and two patients with lung cancer underwent CT-guided interstitial ^125I seeds implantation. All patients were scanned on multi-spiral CT（ Philips, MX 8000） with optical navigating system （ pinpoint）, and treatment plan system, needle, and ^125I seeds （Chinese Academy of Science） were used. The optimal quantity of seeds was calculated by TPS according to the size of tumor. Then, under the guidance of CT,^125I seeds were percutaneously implanted into the tumors for interstitial radiotherapy. CT follow-up examinations were performed 1 months after the therapy. Results All cases were suceeded at 1 month：obvious relies （cR） （ the size of tumor reduced up to 50% ） ,76.3% ;relief（PR） （ the size of tumor reduced by 25% - 50% ）, 17.7% ; slight relief（SD） （ the size of tumor reduced by 1% - 25 % ） ,4.1% ; no effect（PD） （ the size of tumor did not reduce or increase, and clinic symptoms showed no relief）, 1.9%. Conclusion CT-guided interstitial ^125I seeds implanted is a safe, reliable, and effective curative method for lung cancer.

关 键 词：肺癌 组织间照射 ^125I 

分 类 号：R817.54[医药卫生—影像医学与核医学] R734.2[医药卫生—放射医学]